PMCUF:OTC-Pro Medicus Limited (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 115.188

Change

-3.81 (-3.20)%

Market Cap

USD 12.25B

Volume

1.30K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Pro Medicus Limited, a healthcare informatics company, engages in the development and supply of healthcare imaging software, and radiology information (RIS) system software and services to hospitals, imaging centers, and health care groups in Australia, North America, and Europe. The company offers Visage RIS Visage 7 Enterprise Imaging Platform, a healthcare imaging software that provides radiologists, physicians, and clinicians with access and visualization capability for viewing 2-D, 3-D, and 4-D medical images; and picture archive and communication system (PACS)/digital imaging software. It also provides Visage RIS, a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; Promedicus.net, an e-health platform for secure email and integration products. In addition, the company offers Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. The company was incorporated in 1983 and is headquartered in Richmond, Australia.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
MTHRY M3 Inc

-0.02 (-0.29%)

USD 6.94B
SMSZF SMS Co. Ltd

N/A

USD 1.52B
PANHF Ping An Healthcare and Technol..

N/A

USD 1.43B
SMSSY SMS Co., Ltd.

-0.18 (-2.24%)

USD 1.33B
CRWRF Craneware plc

N/A

USD 1.07B
SUSRF Surgical Science Sweden AB (pu..

N/A

USD 0.61B
SFSVF Software Service, Inc.

N/A

USD 0.50B
VHIBF Vitalhub Corp

N/A

USD 0.34B
KSIOF kneat.com inc.

+0.01 (+0.29%)

USD 0.31B
COGZF Cogstate Limited

N/A

USD 0.11B

ETFs Containing PMCUF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 77.90% 82% B 90% A-
Dividend Return 0.41% 25% F 7% C-
Total Return 78.31% 82% B 90% A-
Trailing 12 Months  
Capital Gain 123.93% 87% B+ 93% A
Dividend Return 0.52% 40% F 11% F
Total Return 124.44% 87% B+ 93% A
Trailing 5 Years  
Capital Gain 504.66% 93% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 504.66% 93% A 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 52.81% 77% C+ 77% C+
Dividend Return 53.06% 77% C+ 76% C+
Total Return 0.25% 63% D 7% C-
Risk Return Profile  
Volatility (Standard Deviation) 55.65% 57% F 47% F
Risk Adjusted Return 95.34% 99% N/A 98% N/A
Market Capitalization 12.25B 100% F 92% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.